Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.

ABSTRACT: Melanoma is an aggressive cancer type with a high mortality rate and an elevated resistance to conventional treatment. Recently, promising new tools for anti-melanoma targeted therapy have emerged including inhibitors directed against frequently overexpressed receptors of growth factors implicated in the progression of this cancer. The ineffectiveness of single-targeted therapy prompted us to study the efficacy of treatment with a combination of foretinib, a MET (hepatocyte growth factor receptor) inhibitor, and gefitinib or lapatinib, EGFR (epidermal growth factor receptor) inhibitors. We observed a synergistic cytotoxic effect for the combination of foretinib and lapatinib on the viability and proliferation of the examined melanoma cell lines. This combination of inhibitors significantly

SUBMITTER: Dratkiewicz E 

PROVIDER: S-EPMC5915070 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature